We are solving one of the most important challenges in pharmacology
…Where success is commensurately rewarded (even in early-stage companies)
Pre-clinical company SQZ Biotechnologies recently completed a deal with Roche involving:
- US$125m up-front/near-term;
- US$250m clinical, regulatory and sales milestones per product; and
- US$1bn developmental milestones
Cell Penetrating Peptides (CPPs) sit on the cusp of clinical validation
Sarepta have taken promising pre-clinical results driven by Cell Penetrating Peptides (CPPs)… | …Into the clinic |
mdx mice at 7 weeks of age were treated with a single IV dose of PPMO at 10, 20, 40, or 80 mg/kg and analysed at 30 days post-injection (N=6 mice per group) | i)CPP-PMO (PPMO) is now in Phase 1 trials ii) multiple follow on CPP-PMO programs are scheduled for IND in 2019 "If the [CP]PPMO tech works, it will not only be fantastic for kids with DMD, but it also allows us to move beyond DMD and into other therapeutic areas" Sarepta CEO |
Efficiency of delivery remains the rate-limiting step in the field |
Source:http://investorrelations.sarepta.com/static-files/37f91de4-480e-4429-b453-18ba373fe599
We have the richest and most structurally diverse source library for Cell Penetrating Peptides (CPPs)… | …And we are translating this advantage from the libraries into our 'platform' |
Comparison of efficiency of Phylogica's CPPs (orange) with 'conventional' CPPs (blue) | The 3D protein landscape - One of the many dimensions of drug-like properties we are optimising for using advanced analytics to tailor a CPP for particular cargoes and target tissues |
Our CPPs deliver more cargo inside cells than competitor CPPs |
We have a clear path to translate our differentiation into 'a molecule'
2019
2020
Development stage
MilestoneCargo
Definitive (therapeutic) in vivo read-out
Interim in vivo read-outs
IND-submission
Our technology is highly scalable from this point onwards
Attachments
- Original document
- Permalink
Disclaimer
Phylogica Limited published this content on 16 November 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 16 November 2018 03:58:01 UTC